Osimertinib Has Transformed Lung Cancer Care — But at What Cost to the Heart?
Muhammad Awidi, Hematology and Oncology Fellow at Roswell Park Cancer Center, shared on LinkedIn.
”Osimertinib has changed the landscape for EGFR-mutated lung cancer, but its long-term heart safety has remained uncertain.
In our latest paper, we found that patients treated with osimertinib had higher rates of cardiomyopathy, ischemic heart disease, and heart failure compared with earlier-generation EGFR inhibitors. As survival improves, our findings highlight the need for ongoing cardiovascular monitoring to help prevent late toxicities.
Grateful to my outstanding co-authors Zaid Muhanna, Muntaser Zyoud, and Ahmad Issa three talented medical students I had the privilege to mentor on this project.”
Read the full Abstract here.
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 11:02Stimuli-Induced Remodeling of the Platelet Lipidome in Pulmonary Embolism – ESC
-
Oct 4, 2026, 10:45Join the Bleeding Disorders Advocacy Network! – HFA
-
Oct 4, 2026, 06:12David McIntosh: 900 Plasma Donations One Patient One Lifeline
-
Oct 4, 2026, 06:00Aadil Sheikh: Menopausal Hormone Therapy and Thrombosis Rethinking Route Dose and Risk
-
Oct 4, 2026, 05:27Nirali Thakkar: Influenza and Myocardial Infarction An Unexpected Cardiovascular Connection
-
Oct 4, 2026, 05:03Hisham Fahmi: Thromboprophylaxis in Children With ALL A Risk Adapted Approach
-
Oct 4, 2026, 05:00Mary Cushman: Erin Michos Highlights Rising Heart Disease Mortality Among Younger Women in the US
-
Oct 4, 2026, 04:48Liv Tybjærg Nordestgaard: Is Fasting Necessary Before Blood Sampling?
-
Oct 4, 2026, 04:31Sonal Sonu: Gen Z doesn’t just set trends – Gen Z saves lives